FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

New England Journal of Medicine

Volumn 364, Issue 19, 2011, Pages 1817-1825

  Conroy, Thierry ^a   Desseigne, Françoise ^b   Ychou, Marc ^c   Bouché, Olivier ^e   Guimbaud, Rosine ^f   Bécouarn, Yves ^g   Adenis, Antoine ^h   Raoul, Jean Luc ⁱ   Gourgou Bourgade, Sophie ^c   De La Fouchardière, Christelle ^b   Bennouna, Jaafar ^j   Bachet, Jean Baptiste ^k   Khemissa Akouz, Faiza ^l   Péré Vergé, Denis ^m   Delbaldo, Catherine ⁿ   Assenat, Eric ^d   Chauffert, Bruno ^o   Michel, Pierre ^p   Montoto Grillot, Christine ^q   Ducreux, Michel ^r,s  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CENTRE LÉON BÉRARD   (France)

^c CENTRE VAL D AURELLE   (France)

^d HÔPITAL SAINT ELOI   (France)

^e SERVICE DE DERMATOLOGIE   (France)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g INSTITUT BERGONIÉ   (France)

^h CENTRE OSCAR LAMBRET   (France)

ⁱ CENTRE EUGÈNE MARQUIS   (France)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k HÔPITAL AMBROISE PARÉ   (France)

^l CENTRE HOSPITALIER   (France)

^m CROIX ROUSSE HOSPITAL   (France)

ⁿ HENRI MONDOR HOSPITAL   (France)

^o CENTRE GEORGES FRANÇOIS LECLERC   (France)

^p ROUEN UNIVERSITY HOSPITAL   (France)

^q Bureau d'Etudes Cliniques et Thérapeutiques Groupe Tumeurs Digestives Unicancer   (France)

^r INSTITUT GUSTAVE ROUSSY   (France)

^s UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 79955921754     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1011923     Document Type: Article

References (35)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R. EUROCARE-4: survival of cancer patients diagnosed in 1995-1999: results and commentary. Eur J Cancer 2009;45:931-91.
3. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13. (Pubitemid 27251144)
4. Di Marco M, Di Cicilia R, Macchini M, et al. Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? Oncol Rep 2010;23:1183-92.
5. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007;25:2212-7. (Pubitemid 46954645)
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52. (Pubitemid 46630743)
7. Heinemann V, Boeck S, Hinke A, Labianca R, Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82.
8. Ueno H, Okusaka T, Funakoshi A, et al. A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 2007;59:447-54. (Pubitemid 46127378)
9. Wagener DJT, Verdonk HER, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer: an EORTC early clinical trials group study. Ann Oncol 1995;6:129-32.
10. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004;10: 1121-9. (Pubitemid 38198914)
11. Mans DR, Grivicich I, Peters GJ, Schwartsmann G. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 1999;35:1851-61. (Pubitemid 29512319)
12. Mullany S, Svingen PA, Kaufmann SH, Erlichman C. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 1998;42:391-9. (Pubitemid 28430370)
13. Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 1998;56:1315-22. (Pubitemid 28511268)
14. Ducreux M, Mitry E, Ould-Kaci M, et al. Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 2004;15:467-73. (Pubitemid 38444551)
15. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999;5:1189-96. (Pubitemid 29233237)
16. Ychou M, Conroy T, Seitz JF, et al. An open label phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol 2003;14: 481-9. (Pubitemid 36367429)
17. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin- modulated fluorouracil in advanced pancreatic cancer - a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005;23:1228-36. (Pubitemid 46202280)
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55. (Pubitemid 13149996)
19. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76. (Pubitemid 23073154)
20. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, 2006. (http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.)
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Introduction and methods. In: Early Breast Cancer Trialists' Collaborative Group. Treatment of early breast cancer. Vol. 1. Worldwide evidence 1985-1990. Oxford, England: Oxford University Press, 1990.
24. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics 1985;41: 361-72.
25. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. Brussels: European Organisation for Research and Treatment of Cancer, 2001.
26. Fayers P, Weeden S, Curran D. EORTC QLQ-C30 reference values. Brussels: European Organisation for Research and Treatment of Cancer, 1998.
27. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998;16:139-44. (Pubitemid 28041591)
28. Bonnetain F, Dahan L, Maillard E, et al. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer 2010;46:2753-62.
29. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17. [Erratum, N Engl J Med 2010;363:298.]
30. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002;94:902-10. (Pubitemid 34150843)
31. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009;27: 5513-8.
32. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
33. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unrespectable or metastatic pancreatic cancer. Ann Oncol 2005;16: 1639-45. [Erratum, Ann Oncol 2006;17: 535.]
34. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22: 3776-83. (Pubitemid 41095218)
35. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)